NCT00104650 - Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates | Biotech Hunter

Enrollment

111

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

January 31, 2008

Study Completion Date

March 31, 2010

Conditions

Bone Metastases in Men With Hormone-Refractory Prostate CancerBone Metastases in Subjects With Advanced Breast CancerBone Metastases in Subjects With Advanced Cancer or Multiple Myeloma

Interventions

GENETIC

AMG 162 180 mg (SC) q 12 weeks

A 180 mg AMG 162 (SC) administered every 12 weeks for 2 doses (Day 1 and wk 13) in the treatment phase. If subjected are enrolled in the extension phase, they will continue to receive a 180 mg AMG 162 (SC) administered every 12 weeks for 9 doses.

DRUG

IV Bisphosphonate q 4 weeks

IV Bisphosphonate (eg pamidronate or zoledronic acid) every 4 weeks for 6 doses as described by package insert during the treatment phase. If enrolled to the extension phase, subject will be assigned to the AMG 162 180mg (SC) every 4 weeks for 26 doses.

GENETIC

AMG 162- 180 mg q 4 weeks

A 180 mg AMG 162 (SC) administered every 4 weeks for 6 doses in the treatment phase. If subjected are enrolled in the extension phase, they will continue to receive a 180 mg AMG 162 (SC) administered every 4 weeks for 26 doses.